粗针穿刺活检在射频消融治疗甲状腺微小乳头状癌中的临床应用
Value of Ultrasound-guided Core-needle Biopsy for Evaluating the Performance of Radiofrequency Ablation for Low-risk Papillary Thyroid Microcarcinoma
查看参考文献26篇
|
文摘
|
目的探讨粗针穿刺评价射频消融治疗甲状腺微小乳头状癌疗效的应用价值。方法回顾性分析2016年6月至2018年9月行射频消融(RFA)治疗单发低危甲状腺微小乳头状癌患者190例,随访时间均大于12个月,其中女性142例、男性48例,年龄20~74岁,肿瘤平均体积(106.29±96.15)mm~3。RFA术后1、3、6、12个月及随后每半年行超声和超声造影检查评估消融灶体积、颈部淋巴结及甲状腺实质情况。于术后第3或6个月对消融灶中心部、周边部及周围正常甲状腺实质分别行粗针穿刺(CNB)评价消融疗效。结果患者的平均随访时间为(30.04±12.41)个月,体积由(106.29±96.15)mm~3缩小至(1.47±8.00)mm~3,体积缩小率为(99.08±4.32)%。术后两枚消融灶病理阳性,均出现在消融灶周边部,随即进行补充消融。随访过程中,无患者出现复发转移。所有患者的手术及CNB均顺利进行,无并发症发生。结论CNB是一种便捷有效的评价低危甲状腺微小乳头状癌消融有效性的检查方法,可在消融术后早期发现残留肿瘤。 |
|
其他语种文摘
|
Objective To investigate the clinical value of core-needle biopsy(CNB)for low-risk papillary thyroid microcarcinoma(PTMC)after radiofrequency ablation(RFA).Methods A total of 190 patients(including 142 females and 48 males,20-74 years old)with unifocal low-risk PTMCs[mean volume of(106.29±96.15)mm~3]treated by RFA from June 2016 to September 2018 were evaluated in this study.During the RFA procedure,enlarged ablation was performed.Patients were followed up 1,3,6,12 months after RFA and every 6 months thereafter.The volume of ablation area and the volume reduction ratio(VRR)were calculated.To evaluate the ablation performance,CNB was performed to the central zone,the peripheral zone,and surrounding thyroid parenchyma 3 or 6 months after RFA.Results The mean follow-up time was(30.04±12.41)months.The mean volume of tumor significantly decreased from(106.29±96.15)mm~3 to(1.47±8.00)mm~3.Two ablated tumors were diagnosed to have residue by CNB and underwent additional RFA.No recurrence,metastatic lymph nodes,or distal metastasis were found during the follow-up.All the patients were tolerable to RFA and CNB procedure.Conclusion CNB can be used to evaluate the ablation performance after RFA for low-risk PTMC. |
|
来源
|
中国医学科学院学报
,2021,43(4):584-589 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503X.13277
|
|
关键词
|
超声
;
射频消融
;
甲状腺微小乳头状癌
;
粗针穿刺
|
|
地址
|
1.
中国人民解放军总医院第一医学中心超声诊断科, 北京, 100853
2.
大连医科大学附属第二医院健康管理中心, 辽宁, 大连, 116023
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-503X |
|
学科
|
临床医学;肿瘤学 |
|
基金
|
国家自然科学基金
|
|
文献收藏号
|
CSCD:7043913
|
参考文献 共
26
共2页
|
|
1.
Chmielik E. Heterogeneity of thyroid cancer.
Pathobiology,2018,85(1/2):117-129
|
CSCD被引
7
次
|
|
|
|
|
2.
Bray F. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin,2018,68(6):394-424
|
CSCD被引
4581
次
|
|
|
|
|
3.
Leboulleux S. Papillary thyroid microcarcinoma:time to shift from surgery to active surveillance?.
Lancet Diabetes Endocrinol,2016,4(11):933-942
|
CSCD被引
22
次
|
|
|
|
|
4.
Haugen B R. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer.
Thyroid,2015,26(1):1-133
|
CSCD被引
828
次
|
|
|
|
|
5.
Pacini F. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
Eur J Endocrinol,2006,154(6):787-803
|
CSCD被引
50
次
|
|
|
|
|
6.
Zhang M. Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma:a prospective study.
Thyroid,2016,26(11):1581-1587
|
CSCD被引
35
次
|
|
|
|
|
7.
Kim J H. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery.
Int J Hyperthermia,2017,33(2):212-219
|
CSCD被引
15
次
|
|
|
|
|
8.
Jeong S Y. Radiofrequency ablation of primary thyroid carcinoma:efficacy according to the types of thyroid carcinoma.
Int J Hyperthermia,2018,34(5):611-616
|
CSCD被引
6
次
|
|
|
|
|
9.
Ding M. Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma.
Clin Radiol,2019,74(9):712-717
|
CSCD被引
7
次
|
|
|
|
|
10.
Ma B. Surgical confirmation of incomplete treatment for primary papillary thyroid carcinoma by percutaneous thermal ablation:a retrospective case review and literature review.
Thyroid,2018,28(9):1134-1142
|
CSCD被引
11
次
|
|
|
|
|
11.
董文武. 甲状腺乳头状癌射频消融治疗后再手术5例临床分析.
中国实用外科杂志,2015,35(6):653-655
|
CSCD被引
17
次
|
|
|
|
|
12.
马奔. 原发性甲状腺癌热消融治疗后再手术2例分析.
中国实用外科杂志,2016,36(8):875-879
|
CSCD被引
12
次
|
|
|
|
|
13.
Zhang M. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma:results of over 5 years' follow-up.
Thyroid,2020,30(3):408-417
|
CSCD被引
14
次
|
|
|
|
|
14.
Chu K F. Thermal ablation of tumours:biological mechanisms and advances in therapy.
Nature Reviews Cancer,2014,14(3):199
|
CSCD被引
101
次
|
|
|
|
|
15.
Cibas E S. The 2017 Bethesda system for reporting thyroid cytopathology.
Thyroid,2017,27(11):1341-1346
|
CSCD被引
72
次
|
|
|
|
|
16.
葛明华. 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版).
中国肿瘤,2018,27(10):768-773
|
CSCD被引
28
次
|
|
|
|
|
17.
Kim J H. 2017 Thyroid Radiofrequency Ablation Guideline:Korean society of thyroid radiology.
Korean J Radiol,2018,19(4):632-655
|
CSCD被引
31
次
|
|
|
|
|
18.
Kim H Y. Primary papillary thyroid carcinoma previously treated incompletely with radiofrequency ablation.
J Cancer Res Ther,2010,6(3):310-312
|
CSCD被引
12
次
|
|
|
|
|
19.
Oddo S. A case of thyroid cancer on the track of the radiofrequency electrode 30 months after percutaneous ablation.
J Endocrinol Invest,2017,40(1):101-102
|
CSCD被引
4
次
|
|
|
|
|
20.
Zhou W. Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma:Preliminary results.
Eur Radiol,2017,27(7):2934-2940
|
CSCD被引
11
次
|
|
|
|
|
了解气象卫星更多信息，请访问